Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

The favorable data provided support for two ongoing phase III, randomized, placebo-controlled trials of ESK-001 in ...

A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.